Type 2 Diabetes Quietly Drains Years of Healthy Life, Landmark Australian Study Shows

Type 2 diabetes mellitus has long been recognized as one of the most consequential chronic diseases of the modern era, a condition that steadily erodes blood sugar control, damages blood vessels, and multiplies the risk of heart attack, stroke, kidney failure, and blindness. Yet a new longitudinal investigation from Australia suggests that the true cost of the disease extends well beyond its clinical complications. The study, published in Applied Research in Quality of Life, provides some of the strongest evidence to date that type 2 diabetes measurably diminishes health-related quality of life and lowers health-state utility values over more than a decade of follow-up, findings that carry significant weight for health economists, policymakers, and clinicians tasked with deciding how scarce healthcare dollars should be spent.

The research team, led by Addisu Shunu Beyene of the University of Newcastle and including colleagues from Deakin University, Haramaya University, the University of Southern Queensland, and the University of Melbourne, drew on the Household, Income and Labour Dynamics in Australia Survey, one of the world’s most respected nationally representative panel studies. Rather than relying on a single snapshot in time, the investigators exploited waves 9, 13, 17, and 21 of the survey, capturing data spanning roughly thirteen years of Australian life. The analytical sample comprised 27,564 person-year observations drawn from 11,042 individuals, a scale and temporal depth that allow researchers to distinguish genuine disease effects from the noise of cross-sectional comparisons.

Methodologically, the study stands out for its use of fixed-effects regression models, a technique prized in health and social science research because it controls for all time-invariant characteristics of individuals, whether observed or not. In practical terms, each person in the sample effectively serves as their own control: the analysis asks whether quality of life changes when the same person develops diabetes, net of stable traits such as genetics, early-life circumstances, personality, and enduring socioeconomic background. This design substantially reduces the risk of confounding, one of the most persistent problems in observational studies of chronic disease, although it cannot entirely eliminate biases arising from time-varying unmeasured factors.

The outcome measures were equally rigorous. Health-related quality of life was assessed with the Short Form 36 questionnaire, a widely validated instrument whose physical and mental subscales are summarized in the Physical Component Summary and Mental Component Summary scores. From these responses, the researchers derived the SF-6D health-state utility value, a preference-based index scored between zero and one that represents how much a given health state is valued relative to full health and death. Utility values of this kind are the currency of quality-adjusted life years, or QALYs, the metric underpinning cost-effectiveness evaluations by agencies such as Australia’s Pharmaceutical Benefits Advisory Committee and health technology assessment bodies worldwide.

The central result was unambiguous. Type 2 diabetes was significantly associated with lower Physical Component Summary scores, with a coefficient of −1.01 points and a 95 percent confidence interval running from −1.62 to −0.41. The disease also reduced SF-6D utility values by −0.0080 points, with a confidence interval from −0.0154 to −0.0007. While these utility decrements may appear numerically small, health economists caution that even modest per-person decrements accumulate across millions of affected individuals and across years of remaining life, translating into large population-level losses of quality-adjusted survival. In contrast, the study found no statistically significant association between type 2 diabetes and the Mental Component Summary, indicating that the burden of the disease in this population is concentrated primarily in physical functioning rather than psychological wellbeing.

The subgroup analyses added a crucial layer of nuance. The negative effects on physical quality of life and utility were most pronounced among men and among adults aged 60 years and older, groups that already face elevated vulnerability to the vascular and musculoskeletal consequences of prolonged hyperglycemia. Additional analyses revealed a heavier physical quality-of-life burden among participants with insufficient physical activity, those living with disability, smokers, people who consumed alcohol, and certain income groups. These patterns suggest that diabetes does not act in isolation but compounds existing disadvantages, deepening inequalities in how long and how well people live with the disease.

The biological plausibility behind these findings is well established. Chronic hyperglycemia accelerates atherosclerosis, impairs microvascular circulation, promotes peripheral neuropathy, and contributes to muscle wasting, fatigue, and reduced mobility, all of which directly degrade the physical dimensions of quality of life captured by the SF-36. Diabetes also increases susceptibility to infections, delays wound healing, and raises the likelihood of amputations and vision loss, each of which imposes profound limitations on daily activities. The absence of a significant mental health effect in this study contrasts with some earlier cross-sectional research and may reflect the adaptive capacities of long-term survey respondents, the protective effects of Australia’s healthcare access, or the fixed-effects design filtering out persistent psychological vulnerabilities that correlate with diabetes onset.

What elevates this study’s importance beyond epidemiology is its explicit focus on health economic implications. The authors emphasize that the estimated SF-6D utility decrements provide exactly the kind of evidence needed to populate QALY-based economic evaluations of diabetes prevention and management interventions. Historically, utility inputs for such models have often been borrowed from other countries, other instruments, or cross-sectional data of uncertain quality, introducing uncertainty into cost-effectiveness estimates. By generating nationally representative, longitudinal, within-person estimates from Australian data, the study offers modelers a more defensible foundation for judging whether prevention programs, screening initiatives, new therapies, or lifestyle interventions deliver value for money.

The findings also carry direct implications for clinical practice. The authors argue that health-related quality of life assessment deserves a place in routine diabetes care, not merely as an afterthought but as a core outcome that reflects what matters most to patients. Because the heaviest burdens fell on older men, people with sedentary lifestyles, smokers, and those drinking alcohol, the results support targeted prevention and management strategies that promote regular physical activity, smoking cessation, and moderation of alcohol consumption. In an era when diabetes prevalence continues to climb globally, the message from this thirteen-year Australian journey is clear: the disease steals not only years of life but the quality of the years that remain, and measuring that theft is the first step toward preventing it.

Subject of Research: Impact of type 2 diabetes mellitus on health-related quality of life and health-state utility values in middle-aged and older Australians

Article Title: Decrements in Health-Related Quality of Life and Health-State Utility Value Due to Type 2 Diabetes Mellitus: Implications for Future Health Economic Evaluation

Article References: Beyene, A. S., Ushula, T. W., Roba, H. S., Alam, K., & Keramat, S. A. (2026). Decrements in Health-Related Quality of Life and Health-State Utility Value Due to Type 2 Diabetes Mellitus: Implications for Future Health Economic Evaluation. Applied Research in Quality of Life. https://doi.org/10.1007/s11482-026-10672-w

Image Credits: AI Generated

DOI: 10.1007/s11482-026-10672-w

Keywords: type 2 diabetes, health-related quality of life, SF-6D utility value, HILDA Survey, fixed-effects regression, QALY, health economics, Australia, Physical Component Summary, longitudinal study, health economic evaluation, diabetes complications